In this article, we will list the 5 Best Low Priced Biotech Stocks to Invest In. Please visit 8 Best Low Priced Biotech Stocks to Invest In if you would like to see the extended list and the methodology behind it.
5. ADMA Biologics Inc. (NASDAQ:ADMA)
ADMA Biologics Inc. (NASDAQ:ADMA) is one of the best low priced biotech stocks to invest in. Mizuho cut the price target on ADMA Biologics Inc. (NASDAQ:ADMA) to $24 from $30 on April 13, maintaining an Outperform rating on the shares. The firm cut estimates and price targets for several stocks under its medical devices and diagnostics coverage ahead of Q1 earnings from the group.
ADMA Biologics Inc. (NASDAQ:ADMA) also received a rating update from Cantor Fitzgerald on March 25. The firm downgraded the stock to Neutral from Overweight, without assigning a price target. It spoke with a number of investors after a short report’s claim that ADMA Biologics Inc. (NASDAQ:ADMA) is boosting Asceniv revenues through channel stuffing, and stated that investors are disappointed over the company’s response and lack of direct communication after the report. The firm further contended that although the company put out a statement, they were “hoping to have more specific feedback addressing the direct claims in the report”. The firm also cited the lack of clarity and concerns associated with the increased days’ sales outstanding and accounts receivable for the downgrade.
ADMA Biologics Inc. (NASDAQ:ADMA) is a biopharmaceutical company that manufactures, markets, and develops specialty plasma-derived biologics. Its operations are divided into the following business segments: ADMA BioManufacturing and Plasma Collection Center.
4. Nurix Therapeutics, Inc. (NASDAQ:NRIX)
Nurix Therapeutics, Inc. (NASDAQ:NRIX) is one of the best low priced biotech stocks to invest in. Wells Fargo cut the price target on Nurix Therapeutics, Inc. (NASDAQ:NRIX) to $28 from $29 on April 9, maintaining an Overweight rating on the shares and stating that although management is continuing execution on bexdeg’s chronic lymphocytic leukemia trials with some modest updates expected at EHA, Wells believes bexdeg’s opportunity in immunology and inflammation remains underappreciated. The firm also stated that it sees data from ONC’s BTKdeg BGB-16673 for chronic spontaneous urticaria in the first half of 2026 as a potential upside catalyst.
Nurix Therapeutics, Inc. (NASDAQ:NRIX) also received a rating update from Stifel on April 8, with the firm bringing the price target on the stock down to $34 from $35 while maintaining a Buy rating on the shares. The rating update came after the company reported a GAAP net loss wider than the firm’s and consensus estimates, which was driven primarily by the recognition of lower-than-expected collaborative revenue.
Nurix Therapeutics, Inc. (NASDAQ:NRIX) is a clinical-stage biopharmaceutical company that discovers, develops, and commercializes innovative small molecules and antibody therapies as a novel treatment approach for inflammatory conditions, cancer, and other challenging diseases.
3. Relay Therapeutics, Inc. (NASDAQ:RLAY)
Relay Therapeutics, Inc. (NASDAQ:RLAY) is one of the best low priced biotech stocks to invest in. On April 13, JonesResearch initiated coverage of Relay Therapeutics, Inc. (NASDAQ:RLAY) with a Hold rating and $18 price target. The firm stated that it has a bullish outlook for the company’s pipeline and zovegalisib’s prospects, and cited valuation for the Hold rating following the stock’s recent strength.
For additional perspective, Relay Therapeutics, Inc. (NASDAQ:RLAY) announced in its fiscal Q4 and full year 2025 results that as of December 31, 2025, its cash, cash equivalents, and investments totaled $554.5 million, compared to approximately $781.3 million as of December 31, 2024. The company anticipates its current cash, cash equivalents, and investments to be sufficient to fund its operating expenses and capital expenditure requirements into 2029. Relay Therapeutics, Inc. (NASDAQ:RLAY) also reported that revenue for fiscal Q4 2025 came up to $7.0 million, compared to $0 for the fourth quarter of 2024. Revenue for the full year 2025 was $15.4 million, compared to $10.0 million for the full year 2024.
Relay Therapeutics, Inc. (NASDAQ:RLAY) is a clinical-stage precision medicine company that uses advanced computational and experimental technologies to innovate drug discovery. Its primary focus is on genetic disease indications and targeted oncology. The company’s Dynamo platform integrates a range of cutting-edge experimental and computational approaches to understand protein structure and motion in drug discovery.
2. Biohaven Ltd. (NYSE:BHVN)
Biohaven Ltd. (NYSE:BHVN) is one of the best low priced biotech stocks to invest in. On April 13, Canaccord initiated coverage of Biohaven Ltd. (NYSE:BHVN) with a Buy rating and set a $21 price target on the stock. The firm told investors in a research note that the company is in the process of developing novel therapeutics for obesity, immunology, neuroscience, and oncology indications. Canaccord views the stock as undervalued based on the company’s opakalim opportunity alone, and recommends buying the shares into the focal epilepsy readout, which the firm sees as presenting “significant upside potential.”
Biohaven Ltd. (NYSE:BHVN) also received a rating update from Citi on April 2, with the firm lifting the price target on the stock to $17 from $14 while maintaining a Buy rating on the shares. The firm told investors that it sees an attractive risk/reward at current share levels into the company’s 2026 catalysts. It also said that it sees the recent competitor data in focal epilepsy to be very positive for the company’s Phase 3 opakalim trial, which has a readout in the second half of 2026.
Biohaven Ltd. (NYSE:BHVN) is a global clinical-stage biopharmaceutical company involved in the discovery, development, and commercialization of therapies for people living with neurological and neuropsychiatric diseases.
1. Ocular Therapeutix Inc. (NASDAQ:OCUL)
Ocular Therapeutix Inc. (NASDAQ:OCUL) is one of the best low priced biotech stocks to invest in. Ocular Therapeutix Inc. (NASDAQ:OCUL) announced on April 13 additional positive Week 52 data from the SOL-1 Phase 3 superiority trial of AXPAXLI (also known as OTX-TKI), which is the company’s investigational product candidate for the treatment of wet age-related macular degeneration (wet AMD).
The company reported that the new SOL-1 post-hoc analyses, presented at the 14th Annual Vit-Buckle Society (VBS) Meeting, reinforce the superior durability, strong sustained disease control, and generally well-tolerated safety seen with AXPAXLI in SOL-1. It added that AXPAXLI demonstrated robust CSFT control with a median time of 39 weeks and 46 weeks to ≥30 and ≥75 uM increases from Week 8. In addition, it stated that drug particles are no longer visible in all AXPAXLI subjects with a vitreous floater AE.
Ocular Therapeutix Inc. (NASDAQ:OCUL) stated that the subjects who were treated with AXPAXLI were generally able to maintain loading phase visual acuity gains up to Week 52 across quartile subgroups based on BCVA at screening. The company also said that it is on track to submit an NDA based on SOL-1 alone, which is subject to planned formal discussions with the U.S. FDA, and is consistent with recent FDA public commentary.
Ocular Therapeutix Inc. (NASDAQ:OCUL) is a biopharmaceutical company that develops and commercializes therapies for conditions and diseases related to the eye. The company’s product pipeline includes Dextenza, OTX-TP, and OTX-TIC.
While we acknowledge the potential of OCUL to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than OCUL and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
